COMPUTEX
3.6.2021 10:35:08 CEST | Business Wire | Press release
According to Gartner, by 2023, one-third of companies that have implemented IoT will also have implemented AI in conjunction with at least one IoT project. Data generated from IoT devices will be integrated in various vertical applications and eventually be applied to smart factories, smart healthcare, smart transportation, and smart cities. The first two sessions of COMPUTEX Forum organized by TAITRA, "AIoT Evolution" and "AI Empowerment,” were held on June 2. Top speakers from Micron Technology, Intel, Supermicro, NVIDIA, NXP Semiconductors, Arm, Delta Electronics, and Check Point Software were among the lineup to deep dive into the infinite possibilities of AIoT and AI.
Micron Technology: Driving AI innovation with storage in the new era of data intensive computing
President and CEO of Micron Technology Sanjay Mehrotra pointed out that the world is at the dawn of a new age of data intensive computing. AI and 5G are the two major drivers of this age. With the rapid growth of AI applications, accompanied by numerous challenges, Micron Technology will continue to build a reliable, systematic infrastructure based on memory and storage for a better AI future.
Intel: Embracing infinite computing possibilities with next-gen AI processor
Nash Palaniswamy, Vice President of Intel’s Sales and Marketing Group and General Manager of AI, HPC, Datacenter Accelerators Solutions and Sales, addressed the possibilities of 3rd Gen Intel Xeon Scalable Processor. The latest generation of Xeon is capable of fulfilling AI and high-performance computing needs. Supported by close partnerships and deep integrations with the world’s software leaders and solution providers, Intel delivers fast, consistent, and secure solutions that people trust.
Supermicro: Meeting demands for innovations with an array of products and solutions
Supermicro President and CEO Charles Liang stated that Supermicro will continue to meet customer demand in terms of AI, 5G, and cloud solutions through its leading technology, innovation, high quality, and serviceability. Supermicro will also push forward the development of technology with its partners through collaborations.
NVIDIA: Igniting Industrial Revolution 4.0 with AI
According to Jerry Chen, NVIDIA Head of Global Business Development for Manufacturing and Industrials, AI is the most impactful general-purpose technology, and it will be at the heart of advanced technologies such as 5G, HPC, AIoT, and robotics, propelling industry development and transformation.
NXP Semiconductors: Accelerating Secure Intelligent Edge with New Era of Edge Computing Started
Kurt Sievers, President and CEO of NXP Semiconductors, indicated that AIoT devices are changing the way people live. While it creates great user experience, it is imperative to fully protect data and realize a secure intelligent edge. NXP Semiconductors will also continue to enable a safer and smarter world through breakthrough innovations.
Arm: Accelerating ubiquitous intelligence
Rene Haas, President of Arm IP Products Group, discussed the increasing global demand for computing. The new Armv9 architecture is effective in addressing demanding AI/ML workloads while delivering enhanced security. The next-gen architecture outlines the roadmap for the next decade of computing.
Intelligence-driven manufacturing for advancing into Industry 4.0
According to Dr. Steven Chen, Leader of Intelligent Mobile Machine Cluster, Delta Research Center of Delta Electronics, manufacturers must continue to improve their capabilities to achieve “Manufacturing on Demand.” By adopting design that incorporate standardized, modular and intelligent units, machines can be more scalable and flexible to production changes, as well as data collection & analysis and AI adoption and upgrade, accelerating the progress of an Intelligence-driven manufacturing.
Check Point Software: Managing cybersecurity risks through AI tool
Kev Hau, Check Point Security evangelist, office of the CTO, shared his insights on the trend of cybersecurity in the new normal. AI, machine learning, and big data analytics are all revolutionizing cybersecurity. The machine-learning algorithm of AI is capable of predicting unknown threats in a much broader scope and providing cybersecurity specialists a quick response with increasing accuracy and precision.
AI is reshaping the world. With the democratization of related technologies and AIoT applications, COMPUTEX aims to explore more business opportunities with its global partners.
- All sessions are available online from now: https://virtual.computextaipei.com.tw/events/
- Register for free:
https://virtual.computextaipei.com.tw/
For more information: https://virtual.computextaipei.com.tw/events/
#########
For more information:
COMPUTEX : https://www.computextaipei.com.tw/
InnoVEX : https://www.innovex.com.tw/
About COMPUTEX
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnovexVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
Explore #COMPUTEXVirtual now at https://virtual.computextaipei.com.tw/ .
About TAITRA
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005420/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom